The Risk of Stroke after Acute Myocardial Infarction in Patients with and without Atrial fibrillation: A Nationwide Cohort Study in Taiwan

doi:10.21203/rs.3.rs-157287/v1

Download PDF

Research Article

The Risk of Stroke after Acute Myocardial Infarction in Patients with and without Atrial fibrillation: A Nationwide Cohort Study in Taiwan

https://doi.org/10.21203/rs.3.rs-157287/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 12 Oct, 2021

Read the published version in Journal of the Chinese Medical Association →

Version 1

posted

You are reading this latest preprint version

Background

Both acute myocardial infarction (AMI) and atrial fibrillation (AF) are risks for stroke. The risk of stroke after AMI may be different in patients with or without AF. The aim of this study was to evaluate the impact of AF on stroke in patients after first AMI.

Methods

This is a retrospective nationwide cohort study. A total of 170,472 patients who had the primary diagnosis of first AMI between 2000 and 2012 were enrolled. Among them, 8,530 patients with AF were identified. Propensity score matching technique was used to match 8,530 patients without AF with similar ages and genders. All patients were followed until stroke or 31 December 2012, whichever occurred first. Kaplan–Meier cumulative survival curves were constructed to compare stroke between AMI patients with and without AF.

Results

Overall, 12-year stroke rate was higher in patients with AF than without AF (log rank P-value < 0.001), including in different genders, ages, or intervention subgroups. In patients with AF, those with preexisted AF had higher stroke rates in male gender, age below 65 years, and with intervention subgroups than those with new-onset AF. In Cox proportional-hazard regression analysis, AF was an independent risk factor for stroke after first AMI (hazard ratio, 1.67; 95% confidence interval, 1.5–1.87).

Conclusions

AF significantly increased stroke risks after first AMI. In patients with AF, those with preexisting AF have higher stroke risks in male genders, ages below 65 years, and with interventions than those with new-onset AF.

Cardiac & Cardiovascular Systems

atrial fibrillation

myocardial infarction

stroke

Myocardial infarction (MI) is a risk factor for stroke due to the possibility of cardiac emboli formation within left ventricle because of focal hypokinesia or akinesia after MI. Besides, the coexistent atherosclerosis change of cerebral arteries, which is the major risk of stroke, may also occur in patients with coronary heart disease.^{1, 2} Atrial fibrillation (AF) is a well-known risk factor of stroke due to cardiac emboli formation in the left atrium (LA), especially within LA appendage, due to the loss of rhythmic contractility of LA.³ The risk of stroke after MI in patients with or without AF may be different. The aim of this study was to evaluate the impact of AF on stroke in patients after first MI, through the retrospective analysis of data from the Taiwan National Health Insurance Research Database (NHIRD).

Data source

In Taiwan, the National Health Insurance Program has financed the healthcare for more than 99% residents of Taiwan since 1995. The NHIRD includes detailed information from the medical records of patients admitted to hospitals, including age, sex, diagnosis, intervention procedures, medication prescription, and relevant survival data. The NHIRD provides researchers with deidentified data via encryption of the identification codes to preserve patient anonymity and has been extensively used in epidemiologic studies in Taiwan.^4–6 Our use of the NHIRD data and the informed consent wavier was approved by the Human Research Committee of Kaohsiung Veterans General Hospital and the reference number was VGHKS15-CT12-01. All methods were carried out in accordance with relevant guidelines and regulations.

Definition of AMI Population

All patients admitted to hospitals in Taiwan with the primary diagnosis of acute myocardial infarction (AMI) (ICD-9: 410 to 410.92) between January of 2000 and December of 2012 were enrolled. From this group, who were younger than 20 years old or older than 120 years old, who had doubtful data, whose ICD-9 codes consisted both ST-elevated MI (STEMI) and Non-ST elevated MI (NSTEMI), and who had any previous history of stroke (ICD-9: 430 to 437 or A290 to A294) were excluded, leaving 170,472 patients of AMI (Fig. 1). All ICD-9 codes used for the diagnosis in this study were shown in supplemental Table 1.

Study Population

Among the 170,472 identified patients of the first hospitalization for AMI, 8,530 patients (5%) with atrial fibrillation in discharge diagnosis were identified. Of the remaining 161,942 patients, patients with any diagnosis of AF prior to this admission were excluded, leaving 158,046 control patients for comparison. A propensity score matching technique was used to minimize baseline differences between the control group and the AF group. One-to-one matching was based on the variables of sex and age. The data from 8,530 AMI patients with AF and 8,530 matched controls were, therefore, included in our final analysis. Among 8,530 AMI patients with AF during admission, 6,641 patients who did not have any prior AF diagnosis, were defined as new-onset AF. The remaining 1,889 patients who had the prior AF diagnosis, were defined as preexisting AF (Fig. 1).

Outcome Analysis

All enrolled patients were followed until stroke or 31 December 2012, whichever occurred first. Stroke was defined as the following admission with the first diagnosis code of stroke.

Statistical Analyses

Extraction of the data and statistical analysis were performed by SAS version 9.4 (SAS Institute, Inc., Cary, NC). Descriptive statistics were calculated for all variables, with categorical data reported as percentile values and continuous variables as a mean. Between group differences were evaluated by paired t test for continuous variables and Chi-squared test for categorical variables, with a P-value < 0.05 considered statistically significant. Cox proportional hazard regression analysis was used to calculate the hazard ratio (HR), and associated 95% confidence intervals (95% CI), for significant variables. Kaplan–Meier cumulative survival curves were constructed to compare stroke between AMI patients with AF and those who had not, including subgroup analysis of different genders, ages, and with or without intervention. Log-rank tests with a P < 0.05 were considered statistically significant.

Descriptive Characteristics of Study Group

The descriptive characteristics of the 8,530 patients forming the AMI with AF group (AF group) and the 8,530 matched controls (control group), including types of AMI, with or without intervention therapies [coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)], comorbidities, CHA₂DS₂-VASc scores, and types of medications used, were listed in Table 1 and Supplemental Table 2. Groups were comparable on the primary demographic variables of age and distribution of genders. The ratio of NSTEMI was higher in AF group (66.07% vs. 62.44%, P < 0.001). The ratio of intervention therapy was lower in AF group (40.47% vs. 42.39%, P = 0.0108). Comorbidities including hypertension (30.81% vs. 35.38%, P < 0.0001), diabetes mellitus (DM) (20.2% vs. 29.84%, P < 0.0001), dyslipidemia (8.84% vs. 14.87%, P < 0.0001), and end-stage renal disease (ESRD) (1.41% vs. 1.79%, P = 0.0441) were lower in AF group. On the other hands, comorbidities including heart failure (29.57% vs. 19.64%, P < 0.0001) and chronic obstructive pulmonary disease (COPD) (7.15% vs. 6.19%, P = 0.0119) were higher in AF group. About medications, the use of aspirin (82.91% vs. 77.95%, P < 0.0001), clopidogrel (64.33% vs. 59.34%, P < 0.0001), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) (66.62% vs. 59.5%, P < 0.0001), beta blocker (53.22% vs. 48.36%, P < 0.0001), warfarin (12.26% vs. 2.06%, P < 0.001), Class III antiarrhythmic drugs(AAD) (37.55% vs. 8.56%, P < 0.0001), digoxin (27.21% vs. 8,19%, P < 0.001), and non-dihydropyridine calcium channel blocker(CCB)(21.47% vs. 11.84%, P < 0.0001) were higher in AF group. On the other hands, the use of statin was lower in AF group (30.6% vs. 32.4%, P = 0.0111).

Table 1

Characteristics of patients with first hospitalized AMI with and without AF
Characteristics	Without AF (N = 8,530)	With AF (N = 8,530)	P-value
Gender
Female	3299(38.68%)	3299(38.68%)	1
Male	5231(61.32%)	5231(61.32%)
Age
Age < 65	1961(22.99%)	1961(22.99%)	1
65 ≤ Age < 75	2174(25.49%)	2174(25.49%)
Age ≥ 75	4395(51.52%)	4395(51.52%)
Type of AMI
NSTEMI	5326(62.44%)	5636(66.07%)	< .0001
STEMI	3204(37.56%)	2894(33.93%)
Interventions
Without PCI or CABG	4914(57.61%)	5078(59.53%)	0.0108
PCI or CABG	3616(42.39%)	3452(40.47%)
Comorbidities
Hypertension	3018(35.38%)	2628(30.81%)	< .0001
DM	2545(29.84%)	1723(20.2%)	< .0001
Heart failure	1675(19.64%)	2522(29.57%)	< .0001
Dyslipidemia	1268(14.87%)	754(8.84%)	< .0001
COPD	528(6.19%)	610(7.15%)	0.0119
ESRD	153(1.79%)	120(1.41%)	0.0441
AMI acute myocardial infarction, STEMI ST elevated myocardial infarction, NSTEMI non-ST elevated myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease

We further divided AF group into new-onset AF or preexisting AF subgroups (Table 2 and Supplemental Table 3). There were 6,641 patients in new-onset AF subgroup and 1,889 patients in preexisting AF subgroup. The ratio of female gender was higher in preexisting AF subgroup (41.03% vs. 38.01%, P = 0.0174). The age was older in preexisting AF subgroup (P < 0.0001). The ratio of NSTEMI was higher in preexisting AF subgroup (71.89% vs. 64.42%, P < 0.0001). The intervention therapy ratio was lower in preexisting AF subgroup (35.63% vs. 41.85%, P < 0.0001). About the comorbidities, the ratios of hypertension (32.87% vs. 30.22%, P = 0.0275) and heart failure (35.31% vs. 27.93%, P < 0.0001) were higher and the ratio of dyslipidemia (6.56% vs. 9.49%, P < 0.0001) was lower in preexisting AF subgroup. CHA₂DS₂-VASc score was higher in preexisting AF subgroup (P < 0.0001). The use of aspirin (78.82% vs. 84.07%, P < 0.0001), and class III AAD (27.37% vs. 40.45%, P < 0.0001) were lower in preexisting AF subgroup. On the other hand, the use of warfarin (19.64% vs. 10.16%, P < 0.0001), digoxin (34.09% vs. 25.25%, P < 0.0001), and non-dihydropyridine CCB (23.13% vs. 20.99%, P = 0.0453) were higher in preexisting AF subgroup.

Table 2

Characteristics of patients with new onset AF during admission and with preexisting AF before admission
Characteristics	New onset AF during admission (N = 6,641)	Preexisting AF before admission (N = 1,889)	P value
Gender
Female	2524(38.01%)	775(41.03%)	0.0174
Male	4117(61.99%)	1114(58.97%)
Age
Age < 65	1608(24.21%)	353(18.69%)	< .0001
65 ≤ Age < 75	1674(25.21%)	500(26.47%)
Age ≥ 75	3359(50.58%)	1036(54.84%)
Type of AMI
NSTEMI	4278(64.42%)	1358(71.89%)	< .0001
STEMI	2363(35.58%)	531(28.11%)
Interventions
Without PCI or CABG	3862(58.15%)	1216(64.37%)	< .0001
PCI or CABG	2779(41.85%)	673(35.63%)
Comorbidities
Hypertension	2007(30.22%)	621(32.87%)	0.0275
DM	1362(20.51%)	361(19.11%)	0.1817
Heart failure	1855(27.93%)	667(35.31%)	< .0001
Dyslipidemia	630(9.49%)	124(6.56%)	< .0001
COPD	470(7.08%)	140(7.41%)	0.619
ESRD	97(1.46%)	23(1.22%)	0.4287
AMI acute myocardial infarction, STEMI ST elevated myocardial infarction, NSTEMI non-ST elevated myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease

Stroke Analysis

Overall, the 12-year stroke rate was significant higher in AF group (log rank P < 0.001; Fig. 2, panel A). Among both genders, the rate of stroke was significant higher in the AF group (log rank P < 0.001 in both genders; Fig. 2, panel B and C). Patients were further divided by different age subgroups (age < 65 years, age ≥ 65 and < 75 years, and age ≥ 75 years). The Kaplan–Meier cumulative curves for stroke were significant higher in AF group in these three age subgroups (all log rank P < 0.001) (Fig. 3, panel A, B and C). The rates of stroke were significant higher in AF group either with or without intervention therapy (log rank P < 0.001 in both groups; Fig. 3, panel D and E). Two different type of AF subgroup patients were further analyzed, including new-onset AF and preexisting AF subgroups. In the subgroups of male genders, age below 65 years, and with intervention therapies, patients with preexisting AF have significant higher stroke rates as compared to patients with new-onset AF (Table 3 and Figs. 2 and 3).

Table 3

Comparison of stroke cumulative incidence rate in patients with preexisting AF before admission and new onset AF during admission
Comparison of Stroke cumulative incidence rate	Log-rank P value
Overall
Preexisting AF before admission vs. New onset AF during admission	0.5366
Male
Preexisting AF before admission vs. New onset AF during admission	0.0063*
Female
Preexisting AF before admission vs. New onset AF during admission	0.3054
Age < 65
Preexisting AF before admission vs. New onset AF during admission	0.0091*
65 ≤ Age < 75
Preexisting AF before admission vs. New onset AF during admission	0.4762
Age ≥ 75
Preexisting AF before admission vs. New onset AF during admission	0.5366
Without intervention
Preexisting AF before admission vs. New onset AF during admission	0.69
With intervention
Preexisting AF before admission vs. New onset AF during admission	0.0087*
*P value < 0.05

The Cox proportional hazard regression analysis showed an increased rate of stroke after AMI in patients with one of the following characteristics (Table 4): older age (age ≥ 65 years and < 75 years vs. age < 65 years: HR 1.49; 95% CI, 1.3–1.71) (Age ≥ 75 years vs. age < 65 years: HR 2; 95% CI, 1.76–2.28), diabetes mellitus (HR 1.26; 95% CI, 1.13–1.4), heart failure (HR 1.18; 95% CI, 1.05–1.32), and AF (HR 1.67; 95% CI, 1.5–1.87).

Table 4

Cox Proportional Hazard Regression on Stroke of patients after first AMI
Characteristics (all, N = 17,060)	HR (95% CI)	P-value
Sex (Male vs Female)	0.88(0.79–0.97)	0.0106*
Age (65 ≤ Age < 75 vs age < 65)	1.49(1.3–1.71)	< .0001*
Age (Age ≥ 75 vs age < 65)	2(1.76–2.28)	< .0001*
Hypertension (yes vs no)	1.11(1-1.22)	0.0512
DM (yes vs no)	1.26(1.13–1.4)	< .0001*
Heart Failure (yes vs no)	1.18(1.05–1.32)	0.0067*
Dyslipidemia (yes vs no)	0.97(0.83–1.13)	0.6985
COPD (yes vs no)	1.05(0.86–1.29)	0.6452
ESRD (yes vs no)	1.03(0.62–1.72)	0.9153
Intervention (with vs. without PCI or CABG)	0.9(0.81–1.01)	0.063
AF during admission (yes vs no)	1.67(1.5–1.87)	< .0001*
Aspirin (yes vs no)	0.93(0.81–1.07)	0.3379
Clopidogrel (yes vs no)	0.8(0.72–0.9)	0.0001*
ACEI/ARB (yes vs no)	1.11(0.99–1.24)	0.0777
Beta Blocker (yes vs no)	0.98(0.88–1.08)	0.6354
Statin (yes vs no)	1.09(0.97–1.23)	0.1696
Warfarin (yes vs no)	0.99(0.83–1.17)	0.8583
Class III AAD (yes vs no)	0.91(0.81–1.03)	0.1369
Digoxin (yes vs no)	1.12(0.99–1.27)	0.0804
Non-dihydropyridine CCB (yes vs no)	1.05(0.93–1.19)	0.4222
*P < 0.05
AMI acute myocardial infarction, DM diabetes mellitus, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, AAD antiarrhythmic drug, CCB calcium-channel blocker

Forest plot of HRs was used for subgroup analysis (Fig. 4). In patients with AMI and AF, HRs for stroke were higher in both male and female genders, and different ages (age < 65 years, age ≥ 65 years and < 75 years, and age ≥ 75 years). In patients suffered from AMI, those with AF also had high risks for stroke either with or without hypertension, DM, heart failure, dyslipidemia, and intervention therapies. Furthermore, whether the use of aspirin, clopidogrel, ACEI/ARB, beta-blocker, statin or CCB or not, AF also had higher HRs for stroke events. However, AF did not influence stroke attack in patients with COPD (HR 1.12; 95% CI, 0.76–1.66) and ESRD (HR 2.62; 95% CI, 0.89–7.69), and in patients with the use of warfarin (HR 1.33; 95% CI, 0.82–2.15), Class III AAD (HR 1.15; 95% CI, 0.85–1.53), and Digoxin (HR 1.29; 95% CI, 0.98–1.71).

This study revealed that the 12-year stroke rate in patients after AMI is significant higher in patients with AF than without AF, with a HR of 1.67. This negative impact was also found in both genders, different ages, and either receiving intervention (PCI or CABG) or not. In AF patients, preexisting AF has a significant higher stroke rate compared to new-onset AF in the subgroups of male genders, age below 65 years, and receiving intervention therapies.

New onset and preexisting AF in AMI

Our data revealed that the incidence of AF during hospitalization was 5% (8,530 in 170,472 patients) and the majority was new-onset AF (78%, 6,641 in 8,530 patients). According to the previous study, the incidence of AF during hospitalization for AMI was reported as a incidence ranging from 4–19%.⁷ The increased rate of AF can be resulted from an increased left atrial pressure.⁸ This can either be a direct consequence of atrial ischemia or be indirectly caused by an enhanced left ventricular filling pressure or a restricted left ventricular function.^{9, 10}

In a previous study by Zusman et al., the new onset AF following myocardial infarction was associated with a nearly 35-fold increased risk of stroke during follow-up (mean 41 months; HR 34.6, 95% CI: 4.0-296.8).¹¹ However, the limited number of patients and events (14 events out of 300 patients) made their results seem to be less precise, as evidenced by such a wide 95% CI. In a study with the use of data from Danish National Patients Registry with a total of 89,703 patients with myocardial infarction being analyzed and at the end of 5-year follow-up, new onset AF complicating myocardial infarction was demonstrated as an independent predictor for fetal and non-fetal stroke (HR: 2.34; 95% CI: 2.12–2.57 and HR: 2.47; 95% CI: 2.24–2.73, respectively).¹² Additionally, Luo et al. reported a meta-analysis which showed that new-onset AF was associated with an increased risk of ischemic stroke (risk ratios: 2.84, 95% CI: 1.91–4.23; 6 studies).¹³ About preexisting AF, Tanne et al. reported that chronic AF was associated with significant appearance of stroke/TIA in hospital-discharged survivors of AMI (odds ratio: 5.71, 90% CI: 1.55–21.01).¹⁴ Our data included both patients with new-onset and preexisting AF, with a longer follow-up duration (up to 12 years) and a high amount of patients with AF (8,530 patients). The stroke risk after AMI in our study was significant higher in patients with AF than those without AF, with a HR of 1.67 (95% CI, 1.5–1.87).

AMI Patients with preexisting AF may have the presentation of previous diastolic dysfunction and cardiomyopathy. On the other hand, AMI patients with new-onset AF during is due to acute change at the time of AMI, including left atrial ischemia or overload, as well as neuroendocrine activation and tachycardia due to hemodynamic instability. Therefore, preexisting AF and new-onset AF may influence outcomes differently. To our knowledge, there was only one report directly compare preexisting and new-onset AF in the influence of stroke in patients with AMI by Gourronc el al. They have compared preexisting AF, new-onset AF and AF-free patients with AMI. The results showed that there was no significant difference in respect of stroke between preexisting AF, new-onset AF, and AF-free patients (2.2%, 0.5%, and 0.8%, respectively, p = 0.327).¹⁵ Our data showed that in AMI patients with AF, including new-onset and preexisting, have significant higher stroke rates as compared to those without AF. Our data was different from Gourronc et al. may be because that we have much more patients enrolled (8,530 AF patients in our study as compared to 436 patients with AF in their study) and much longer follow-up durations (up to 12 years in our study as compared to 1 year in their study).

Our study showed that in the subgroup of male, age younger than 65 years and with intervention therapies, AMI patients with prior AF have significant higher stroke rate in the subgroup than those with new-onset AF (Table 4). Besides, AMI patients with prior AF have higher ratios of female gender, older ages, NSTEMI, and heart failure and lower ratios of intervention therapies and dyslipidemia. The CHA₂DS₂-VASc scores were significant higher in prior AF group as compared to new-onset AF group. Lau et al. reported that in patients with acute coronary syndrome, those with prior AF had significant higher ratio of older ages, female gender and had significant lower ratio of intervention therapy.¹⁶ The results were compatible with our study. As a result, patients with prior AF tend to be more fragile and could explain the significant higher stroke rate in male, younger, and intervention therapy than patients with new onset AF.

Limitations

There are several limitations in this study. First, although previous study had confirmed the accuracy of NHIRD as a valid resource for research of cardiovascular disease¹⁷, the relevant clinical variables such as cardiac biomarkers, left ventricular ejection fraction, and Killip grade were unavailable and these variables had important influences on the occurrence of stroke. Second, the type of AF did not present in this study. However, according to the previous study, the type of AF did not significantly affect the risk of stroke and should not influence the decision of stroke prevention.¹⁸ Third, the anticoagulation therapy in this study period for AF patients was mainly warfarin. However, non-Vitamin K oral anticoagulants are now used widely in the prevention of stroke in patients with AF and percentage of anticoagulants use has been largely increased in recent years.¹⁹ The clinical practice nowadays may affect the rates of stroke in patients with AF. However, it remains challenging issue to use antiplatelet and anticoagulant therapy in AMI patients with AF, which need to be investigated in further large-scale trail.

This study demonstrated that the 12-year stroke rate in patients after AMI is significant higher in patients with AF than without AF, which could also be found in different subgroups, including both genders, different ages, comorbidities and receiving interventions (PCI or CABG). In patients with AF, those with preexisting AF before admission have higher risks of stroke in subgroups of male genders, younger ages, and with intervention therapies than those with new-onset AF during admission.

MI myocardial infarction,AFatrial fibrillation, LA left atrium, NHIRD National Health Insurance Research Database,AMI acute myocardial infarction, STEMI ST elevated myocardial infarction, NSTEMI non-ST elevated myocardial infarction, HRhazard ratio, CIconfidence interval, CABG coronary artery bypass graft, PCI percutaneous coronary intervention,DM diabetes mellitus, ESRD end-stage renal disease,COPD chronic obstructive pulmonary disease, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, AADantiarrhythmic drug, CCB calcium-channel blocker

Ethics approval and consent to participate: The Taiwan National Health Insurance Research Database (NHIRD) provides researchers with deidentified data via encryption of the identification codes to preserve patient anonymity and has been extensively used in epidemiologic studies in Taiwan. Our use of the NHIRD data and the informed consent waiver was approved by the Human Research Committee of Kaohsiung Veterans General Hospital and the reference number was VGHKS15-CT12-01. All methods were carried out in accordance with relevant guidelines and regulations.
Consent for publication: Not applicable
Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Competing interests: The authors declare that they have no competing interests.
Funding: This study was supported by grants from the Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, i.e., Grants VGHKS 212347-23, 106-084, 106-142, 106-D01-3, 106-160, 106-156, 106-062, 105-139, 106-159 and the Ministry of Science and Technology, i.e., Grants Most 105-2314-B-075B-006 and Most 105-2314-B-075B-007
Authors' contributions: Conceptualization: C-CH, H-WC. Methodology: H-WT, L-KC. Software: C-CH, H-WT. Validation: C-CC, K-FY. Formal analysis: C-CH, H-WT, H-WC. Investigation: C-CC, K-FY. Resources: H-WC. Data curation: C-CH, H-WT, L-KC, C-CC, K-FY. Writing (original draft preparation): C-CH, H-WT, L-KC. Writing (review and editing): H-WC, C-CC, K-FY. Visualization: C-CH, H-WT, H-WC. Supervision: H-WC. Project administration: H-WC. Funding acquisition: H-WC.
Acknowledgements: We would like to thank Yong-Chih Chiu for her expert statistical assistance.

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 esc guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the european society of cardiology (esc). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 esc guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with st-segment elevation of the european society of cardiology (esc). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 esc guidelines for the management of atrial fibrillation developed in collaboration with eacts. Europace. 2016 Nov;18(11):1609-1678. doi: 10.1093/europace/euw295. Epub 2016 Aug 27.
Wang MT, Tsai CK, Kuo SH, Huang WC, Lin KC, Hung WT, et al. The dipyridamole added to dual antiplatelet therapy in cerebral infarction after first acute myocardial infarction: A nationwide, case-control study. Frontiers in neurology. 2018;9:1003
Liu ES, Chiang CH, Hung WT, Tang PL, Hung CC, Kuo SH, et al. Comparison of long-term mortality in patients with acute myocardial infarction associated with or without sepsis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2019;79:169-178
Kuo SH, Hung WT, Tang PL, Huang WC, Yang JS, Lin HC, et al. Impact of hepatitis c virus infection on long-term mortality after acute myocardial infarction: A nationwide population-based, propensity-matched cohort study in taiwan. BMJ open. 2018;8:e017412
Jabre P, Roger Véronique L, Murad Mohammad H, Chamberlain Alanna M, Prokop L, Adnet F, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction. Circulation. 2011;123:1587-1593
Hod H, Lew AS, Keltai M, Cercek B, Geft IL, Shah PK, et al. Early atrial fibrillation during evolving myocardial infarction: A consequence of impaired left atrial perfusion. Circulation. 1987;75:146-150
Aronson D, Mutlak D, Bahouth F, Bishara R, Hammerman H, Lessick J, et al. Restrictive left ventricular filling pattern and risk of new-onset atrial fibrillation after acute myocardial infarction. The American Journal of Cardiology.107:1738-1743
Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: Results from the apex-ami trial. European Heart Journal. 2009;30:2019-2028
Zusman O, Amit G, Gilutz H, Zahger D. The significance of new onset atrial fibrillation complicating acute myocardial infarction. Clin Res Cardiol. 2012 Jan;101(1):17-22. doi: 10.1007/s00392-011-0357-5. Epub 2011 Sep 11.
Bang Casper N, Gislason Gunnar H, Greve Anders M, Bang Christian A, Lilja A, Torp‐Pedersen C, et al. New‐onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89 703 patients with long‐term follow‐up: A nationwide study. Journal of the American Heart Association.3:e000382
Luo J, Li H, Qin X, Liu B, Zhao J, Maihe G, et al. Increased risk of ischemic stroke associated with new-onset atrial fibrillation complicating acute coronary syndrome: A systematic review and meta-analysis. International Journal of Cardiology. 2018;265:125-131
Tanne D, Goldbourt U, Zion M, Reicher-Reiss H, Kaplinsky E, Behar S. Frequency and prognosis of stroke/tia among 4808 survivors of acute myocardial infarction. The sprint study group. Stroke. 1993;24:1490-1495
Gourronc Y, Grall S, Ingremeau D, Desprets L, Prunier F, Furber A, et al. De novo atrial fibrillation as an independent prognostic marker after st-segment elevation myocardial infarction: Results from the rima registry. Journal of cardiology. 2019;74:123-129
Lau DH, Huynh LT, Chew DP, Astley CM, Soman A, Sanders P. Prognostic impact of types of atrial fibrillation in acute coronary syndromes. Am J Cardiol. 2009;104:1317-1323
Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. J Epidemiol. 2014;24(6):500-7. Epub 2014 Aug 30.
Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, et al. Pattern of atrial fibrillation and risk of outcomes: The loire valley atrial fibrillation project. Int J Cardiol. 2013;167:2682-2687
Chiang C-E, Wu T-J, Ueng K-C, Chao T-F, Chang K-C, Wang C-C, et al. 2016 guidelines of the taiwan heart rhythm society and the taiwan society of cardiology for the management of atrial fibrillation. Journal of the Formosan Medical Association.115:893-952

No competing interests reported.

ManuscriptforBMCCVD20210211titlepageandsupplymentdata.docx

Download PDF

Journal Publication

published 12 Oct, 2021

Read the published version in Journal of the Chinese Medical Association →

Version 1

posted

You are reading this latest preprint version

The Risk of Stroke after Acute Myocardial Infarction in Patients with and without Atrial fibrillation: A Nationwide Cohort Study in Taiwan

Status:

Journal Publication

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

Background

Methods

Data source

Definition of AMI Population

Study Population

Outcome Analysis

Statistical Analyses

Results

Descriptive Characteristics of Study Group

Stroke Analysis

Discussion

New onset and preexisting AF in AMI

Limitations

Conclusions

List Of Abbreviations

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1